Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Algernon’s business model is based on drug re-purposing, finding new uses for know drugs





 

Bullboard - Investor Discussion Forum Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > Hospitals running out of Oxygen
View:
Post by MoneyTalks22 on Dec 31, 2020 12:56pm

Hospitals running out of Oxygen

Looking forward to full data soon.  To recap Mackie research report on Ifenprodil Positive trending...  Results show that on day 15, fewer patients needed mechanical ventilation. Additionally, the NEWS (National Early Warning Score) used to monitor patients, was decreasing more quickly, which could translate to faster recovery for patients. (so hospitals would use less oxygen)
Comment by Rockafellow on Dec 31, 2020 3:20pm
If they were given this pill they wouldn need oxygen... ... .. Would they.. ! ! Haven't heard anything on intervenice injection
Comment by talisman47 on Dec 31, 2020 3:24pm
In the latest ProActive news a paragraph in it says The Vancouver-based drug re-purposing company has filed new intellectual property rights globally for Ifenprodil for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. https://ca.paidpromotionalmessages.com/companies/news/937501/algernon-rapidly-advances-ifenprodil-as-a ...more  
Comment by TheBearInTheWoods on Dec 31, 2020 3:26pm
I like how the link says it all! " Paid Promotion" lmao! i clicked on the advertisement a couple times to make them 20 cents 
Algernon Pharmaceuticals Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Connect with C.AGN


PIPELINE TARGETED DISEASES MEDIA MANAGEMENT

CEO Clips: DMT Clinical Trial

CEO Q&A Interview with Chris Moreau

Investor Presentation

Download the latest Investor Presentaion

Algernon Highlights: The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Investment Opportunity

The Algernon Value Proposition



  • Advancing new drug treatments for billion dollar global disease markets.
  • Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues.
  • Conducting multiple phase II clinical trials.
  • Highly capital efficient business model.
  • Experienced management team & globally recognized medical advisory board.

Facebook

Contact Us